CytomX Therapeutics
CTMX
114 hedge funds and large institutions have $275M invested in CytomX Therapeutics in 2021 Q3 according to their latest regulatory filings, with 10 funds opening new positions, 36 increasing their positions, 45 reducing their positions, and 17 closing their positions.
4.35% less ownership
Funds ownership: 87.2% → 82.85% (-4.4%)
7% less funds holding
Funds holding: 122 → 114 (-8)
20% less repeat investments, than reductions
Existing positions increased: 36 | Existing positions reduced: 45
23% less capital invested
Capital invested by funds: $359M → $275M (-$83.8M)
41% less first-time investments, than exits
New positions opened: 10 | Existing positions closed: 17
96% less call options, than puts
Call options by funds: $9K | Put options by funds: $222K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
+$5.23M |
| 2 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$2.68M |
| 3 |
Victory Capital Management
San Antonio,
Texas
|
+$2.14M |
| 4 |
ACM
Altium Capital Management
New York
|
+$1.99M |
| 5 |
Millennium Management
New York
|
+$1.82M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
-$10.4M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$4.12M |
| 3 |
Squarepoint
New York
|
-$3.79M |
| 4 |
State Street
Boston,
Massachusetts
|
-$3.1M |
| 5 |
Morgan Stanley
New York
|
-$2.77M |
CTMX Hedge Fund Activity: Q3 2021 in Review
114 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in CytomX Therapeutics (CTMX) for Q3 2021, worth a combined $275M — down 23% from $359M a quarter earlier.
Sellers outnumbered buyers: 17 funds closed out of CTMX and 10 opened new positions — a net loss of 7 holders — while 45 trimmed existing stakes and 36 added.
The largest buyer was Candriam SCA, adding an estimated $5.23M. The largest seller was Perceptive Advisors, exiting entirely with an estimated $10.4M sold.
- 114 institutional investors held CytomX Therapeutics (CTMX) as of Q3 2021, down from 122 in Q2 2021.
- Funds reported $275M of CytomX Therapeutics stock for Q3 2021, down 23% quarter-over-quarter.
- 10 funds opened new CytomX Therapeutics positions in Q3 2021 and 17 closed out, a net change of -7 holders.
- The largest CytomX Therapeutics buyer in Q3 2021 was Candriam SCA, an estimated $5.23M added.
- The largest CytomX Therapeutics seller in Q3 2021 was Perceptive Advisors, an estimated $10.4M sold.
Based on aggregated 13F filings for Q3 2021.